TriangleSystemic (ICI)-based therapy… (NCT07250477)
Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment. trial for Non-small Cell Lung Cancer Stage IIIC (NCT07250477). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable stage IIIC or metastatic non-small-cell lung cancer before systemic treatment for advanced disease. Specified targetable genetic alterations are excluded.
The idea: random assignment compares standard treatment selection with selection guided by a blood-protein test and a chemotherapy-toxicity assessment. These tools help choose immune-checkpoint treatment, alone or with chemotherapy or another checkpoint drug. Researchers compare time without progression. The study tests treatment selection, not a new drug.
This phase 2 study plans 56 patients. Surbhi Singhal leads at UC Davis in Sacramento; four US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.